Patents by Inventor Johannes Herkel
Johannes Herkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11852634Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.Type: GrantFiled: October 27, 2020Date of Patent: December 26, 2023Assignees: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-EppendorfInventors: Eran Ovadia, Irun R. Cohen, Johannes Herkel, Raanan Margalit, Meirav Pevsner-Fischer
-
Publication number: 20210041455Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.Type: ApplicationFiled: October 27, 2020Publication date: February 11, 2021Applicants: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-EppendorfInventors: Eran OVADIA, Irun R. COHEN, Johannes HERKEL, Raanan MARGALIT, Meirav PEVSNER-FISCHER
-
Patent number: 10898436Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.Type: GrantFiled: May 24, 2018Date of Patent: January 26, 2021Assignee: Topas Therapeutics GmbHInventors: Barbara Freund, Jörg Heeren, Peter Nielsen, Antonella Carambia, Johannes Herkel, Oliver Bruns, Ansgar Lohse, Stefan Lüth, Horst Weller, Sunhild Salmen
-
Publication number: 20190204340Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.Type: ApplicationFiled: March 14, 2019Publication date: July 4, 2019Applicants: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-EppendorfInventors: Eran OVADIA, Irun R. COHEN, Johannes HERKEL, Raanan MARGALIT, Meirav PEVSNER-FISCHER
-
Patent number: 10288622Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogs and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.Type: GrantFiled: October 15, 2015Date of Patent: May 14, 2019Assignees: Yeda Research and Development Co. Ltd., Universitätsklinikum Hamburg-EppendorfInventors: Eran Ovadia, Irun R. Cohen, Johannes Herkel, Raanan Margalit, Meirav Pevsner-Fischer
-
Publication number: 20180325821Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.Type: ApplicationFiled: May 24, 2018Publication date: November 15, 2018Inventors: Barbara Freund, Jörg Heeren, Peter Nielsen, Antonella Carambia, Johannes Herkel, Oliver Bruns, Ansgar Lohse, Stefan Lüth, Horst Weller, Sunhild Salmen
-
Patent number: 10004689Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.Type: GrantFiled: November 14, 2012Date of Patent: June 26, 2018Assignee: TOPAS THERAPEUTICS GmbHInventors: Barbara Freund, Jörg Heeren, Peter Nielsen, Antonella Carambia, Johannes Herkel, Oliver Bruns, Ansgar Lohse, Stefan Lüth, Horst Weller, Sunhild Salmen
-
Publication number: 20160033529Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.Type: ApplicationFiled: October 15, 2015Publication date: February 4, 2016Applicants: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF, YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Eran OVADIA, Irun R. COHEN, Johannes HERKEL, Raanan MARGALIT, Meirav PEVSNER-FISCHER
-
Publication number: 20150297693Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: ApplicationFiled: June 30, 2015Publication date: October 22, 2015Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Johannes HERKEL, Irun R. COHEN, Varda ROTTER, Ansgar W. LOHSE, Neta EREZ, Avishai MIMRAN, Na'aman KAM
-
Publication number: 20140294982Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.Type: ApplicationFiled: November 14, 2012Publication date: October 2, 2014Inventors: Barbara Freund, Jörg Heeren, Peter Nielsen, Antonella Carambia, Johannes Herkel, Oliver Bruns, Ansgar Lohse, Stefan Lüth, Horst Weller, Sunhild Salmen
-
Patent number: 8790653Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: GrantFiled: November 1, 2011Date of Patent: July 29, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Publication number: 20140120126Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.Type: ApplicationFiled: January 2, 2014Publication date: May 1, 2014Applicants: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Irun R. Cohen, Bracha Rager-Zisman, Angel Porgador, Johannes Herkel
-
Publication number: 20140088017Abstract: The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.Type: ApplicationFiled: May 23, 2012Publication date: March 27, 2014Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.Inventors: Eran Ovadia, Irun R. Cohen, Johannes Herkel, Raanan Margalit, Melray Pevsner-Fishcher
-
Patent number: 8652439Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.Type: GrantFiled: June 20, 2011Date of Patent: February 18, 2014Assignees: Yeda Research and Development Co. Ltd., B.G. Negev Technologies and Applications Ltd.Inventors: Irun R. Cohen, Bracha Rager-Zisman, Angel Porgador, Johannes Herkel
-
Publication number: 20120171233Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: ApplicationFiled: November 1, 2011Publication date: July 5, 2012Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. at The Weizmann Institute of ScienceInventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Patent number: 8067008Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides.Type: GrantFiled: August 23, 2005Date of Patent: November 29, 2011Assignee: YEDA Research and Development Co.Inventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam
-
Publication number: 20110256165Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.Type: ApplicationFiled: June 20, 2011Publication date: October 20, 2011Applicants: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., Yeda Research and Development Co., Ltd. at the Weizmann Institute of ScienceInventors: Irun R. Cohen, Bracha Rager-Zisman, Angel Porgador, Johannes Herkel
-
Publication number: 20090098116Abstract: The invention relates to the use of an immunogen selected from the group consisting of (i) an anti-p53 mAb; (ii) a fragment of an anti-p53 mAb; (iii) a peptide based on a CDR of the heavy or light chain of an anti-p53 mAb, which peptide is capable of eliciting antibodies to p53; and (iv) a DNA molecule coding for the variable (V) region of an anti-p53 mAb in a suitable gene delivery vehicle, for the preparation of a pharmaceutical composition useful for induction of anti-tumor immunity in mammals, for activating an enhanced immune response to a p53 molecule in mammals, and/or for induction of immune responses to mutated and wild-type forms of a p53 in mammals. The use of anti-p53 mAbs and novel peptides based on the CDR2 and CDR3 of the heavy chains and CDR3 of the light chains of different anti-p53 mAbs are disclosed.Type: ApplicationFiled: November 20, 2007Publication date: April 16, 2009Applicant: Yeda Research and Development Co., Ltd.Inventors: Irun R. Cohen, Varda Rotter, Roland Wolkowicz, Pedro Ruiz, Neta Erez-Alon, Johannes Herkel
-
Publication number: 20080279878Abstract: The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses.Type: ApplicationFiled: February 21, 2006Publication date: November 13, 2008Applicants: B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., YEDA RESEARCH AND DEVELOPMENT CO. LTD. at The Weizmann Institute of ScienceInventors: Irun R. Cohen, Bracha Rager-Zisman, Angel Porgador, Johannes Herkel
-
Publication number: 20080267983Abstract: The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing peptides recognized by monoclonal anti-DNA antibodies, the peptides having anti-apoptotic and anti-inflammatory activity. The invention further provides antibody molecules and uses thereof for the isolation of such peptides.Type: ApplicationFiled: August 23, 2005Publication date: October 30, 2008Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Johannes Herkel, Irun R. Cohen, Varda Rotter, Ansgar W. Lohse, Neta Erez, Avishai Mimran, Na'aman Kam